Century Therapeutics Updates ATM Program, Authorizing Sale of Up to $131.6M in Stock

summarizeSummary

Century Therapeutics filed a prospectus supplement for its existing At-The-Market (ATM) equity offering program, allowing it to sell up to an additional $131.6 million in common stock.

check_boxKey Events · Financing and Capital Events · IPSC

• ATM Program Update

  The company filed a new prospectus supplement dated March 26, 2026, for its existing At-The-Market (ATM) equity offering program, in connection with a new shelf registration statement that became effective on January 9, 2026.

• Significant Remaining Capacity

  Century Therapeutics is authorized to sell up to an additional $131,619,741 in common stock under the ATM program. The program initially allowed for up to $150,000,000, with $18,380,259 already sold.

• Potential Dilution

  If all authorized shares were issued under the remaining capacity, it would represent a potential dilution of approximately 35.5% relative to the company's current market capitalization.

• Existing Sales Agreement

  This is an update to an existing program established on July 1, 2022, not a new launch.

auto_awesomeAnalysis · IPSC · Life Sciences

This filing updates Century Therapeutics' At-The-Market (ATM) equity offering program, formalizing the remaining capacity under a new shelf registration statement. The authorization to sell up to $131.6 million in common stock represents a substantial potential dilution of approximately 35.5% relative to the company's current market capitalization if fully utilized. While the ATM program itself is not new, the confirmation of such a significant remaining amount creates an overhang on the stock, as the company may issue shares into the market over time. This capital raise is likely intended to provide financial flexibility and extend the company's operational runway.